Table 1.
Comparison of general clinical data between groups
| Variable | Control group (n=55) | PCSK9 inhibitor group (n=55) | χ2/t | P |
|---|---|---|---|---|
| Age (years) | 61.23±10.34 | 60.45±11.67 | 0.371 | 0.711 |
| Male | 36 (65.4) | 38 (69.1) | 0.165 | 0.685 |
| BMI (kg/m2) | 25.31±1.74 | 24.93±1.68 | 1.165 | 0.247 |
| Past medical history | ||||
| Hypertension | 25 (45.5) | 28 (50.9) | 0.328 | 0.567 |
| Diabetes | 4 (7.3) | 6 (10.9) | 0.440 | 0.507 |
| Smoking | 23 (41.8) | 21 (28.2) | 0.152 | 0.697 |
| cTnI (ng/L) | 5.51±2.33 | 5.64±2.17 | -0.303 | 0.763 |
| NT-proBNP (ng/L) | 546.34±72.23 | 524.65±69.77 | 1.602 | 0.112 |
| Creatinine (µmol/L) | 65.64±8.69 | 67.78±7.78 | -1.361 | 0.176 |
| Culprit vessel | ||||
| Left main stem | 1 (1.8) | 1 (1.8) | - | 1 |
| Left anterior descending | 19 (34.5) | 20 (36.4) | 0.040 | 0.841 |
| Left circumflex | 10 (18.2) | 9 (16.4) | 0.064 | 0.800 |
| Right | 17 (30.9) | 18 (32.7) | 0.042 | 0.838 |
| Branch lesions | 8 (14.5) | 7 (12.7) | 0.077 | 0.781 |
| Stent number | 1.62±0.55 | 1.56±0.59 | 0.552 | 0.582 |
| D-to-B time (min) | 63.45±5.67 | 62.87±5.48 | 0.546 | 0.587 |
| Postoperative medication use | ||||
| Aspirin | 55 (100) | 55 (100) | - | 1 |
| Clopidogrel | 11 (20) | 13 (23.6) | 0.213 | 0.644 |
| Ticagrelor | 44 (80) | 42 (76.4) | 0.213 | 0.644 |
| β-blockers | 53 (96.4) | 52 (94.5) | 0.210 | 0.647 |
| ACEI/ARB | 36 (65.5) | 37 (67.3) | 0.041 | 0.840 |
Note: All data are presented as n (%) or mean ± SD; - indicates data not obtained. Abbreviations: ARB, angiotensin II receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; BMI, body mass index; cTnI, cardiac troponin I; NT-proBNP, N-terminal pro b-type natriuretic peptide.